Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)
Clinical trial NCT04639986 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04639986
- Sponsor
- Gilead Sciences
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-11-23
- Primary completion
- 2026-12-01
- Enrollment
- 331
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.